common
cold
acut
viral
infect
upper
respiratori
tract
urti
usual
selflimit
european
posit
paper
rhinosinus
nasal
polyp
epo
common
cold
defin
acut
viral
rhinosinus
symptom
last
less
day
frequent
human
ill
approxim
million
affect
individu
annual
usa
result
associ
signific
burden
term
medic
visit
well
work
school
absente
increas
frequenc
overal
impact
rel
mild
clinic
entiti
consider
moreov
lack
establish
diagnost
procedur
specif
therapi
result
use
divers
overthecount
medic
wherea
signific
number
medic
visit
result
inappropri
unnecessari
antibiot
prescript
contribut
antibiot
overus
microbi
resist
final
common
cold
trigger
sever
even
fatal
diseas
individu
preexist
condit
reason
prevent
effect
treatment
condit
import
unmet
need
sever
studi
demonstr
adult
usual
experi
urti
per
year
wherea
children
consider
depend
age
experi
prolong
symptom
rate
common
cold
per
year
usual
declin
age
risk
factor
includ
daycar
attend
genet
factor
psycholog
stress
smoke
heavi
physic
train
list
pathogen
may
caus
common
cold
symptom
includ
human
rhinovirus
rv
respiratori
syncyti
viru
rsv
influenza
virus
parainfluenza
virus
coronavirus
adenovirus
less
frequent
enterovirus
coxsackievirus
echovirus
bocaviru
ebv
human
metapneumoviru
hmpv
implic
howev
among
causal
agent
rv
common
case
north
hemispher
incid
common
cold
low
summer
increas
late
augustbegin
septemb
earli
spring
factor
contribut
increas
incid
urti
colder
month
includ
time
spent
indoor
result
higher
possibl
intimaci
infect
individu
increas
level
environment
humid
low
indoor
moistur
favor
surviv
virus
coronaviru
infect
mainli
seen
winter
earli
spring
wherea
enteroviru
respiratori
infect
occur
primarili
earli
autumn
summer
infuenza
season
novemb
march
wherea
parainfluenza
piv
usual
isol
autumn
wherea
caus
outbreak
spring
earli
summer
rsv
hmpv
peak
incid
decemb
februari
similarli
adenovir
respiratori
infect
peak
incid
late
winter
spring
earli
summer
human
bocaviru
hbov
urti
common
winter
frequent
coinfect
winter
rv
main
caus
cold
temper
climat
rv
infect
peak
earli
fall
spring
second
smaller
peak
summer
month
wherea
tropic
region
mainli
present
raini
month
nevertheless
rv
common
virus
found
respiratori
tract
independ
season
transmiss
virus
caus
urti
may
occur
via
inhal
viralparticl
hand
contact
pathophysiolog
common
cold
repres
dynam
interplay
host
immun
infect
viru
fig
consider
amount
inform
come
studi
rv
infect
volunt
deposit
nasopharynx
rv
attach
specif
receptor
epitheli
cell
intracellular
adhes
receptor
rv
major
serotyp
lowdens
lipoprotein
ldl
receptor
rv
minor
serotyp
yet
unknown
receptor
typec
rv
initi
inflamm
via
nfkbdepend
mechan
contrast
respiratori
virus
rsv
influenza
rv
major
cytopath
effect
upper
respiratori
tract
airway
epitheli
cell
thu
recogn
common
cold
symptom
caus
cytopath
effect
rv
human
cell
rather
inflammatori
respons
howev
rv
disrupt
epitheli
barrier
function
facilit
epitheli
cell
exposur
bacteria
promot
secondari
bacteri
infect
well
extern
stimuli
irrit
allergen
common
cold
symptom
indistinguish
among
differ
viral
caus
includ
sore
throat
nasal
congest
rhinorrhea
sneez
cough
lowgrad
fever
malais
headach
follow
inocul
incub
period
virus
vari
significantli
hour
influenza
b
day
influenza
day
coronaviru
day
rsv
pai
day
adenoviru
wherea
h
usual
h
rv
symptom
peak
day
postinocul
gener
last
day
occasion
longer
rv
also
detect
asymptomat
children
adult
although
immunocompet
host
common
cold
mild
usual
selflimit
link
sever
complic
acut
otiti
media
aom
present
onethird
viral
urti
children
result
chang
middl
ear
pressur
eustachian
tube
function
increas
suscept
bacteri
coinfect
middl
ear
similarli
sinus
frequent
present
effus
comput
tomographi
ct
magnet
reson
imag
mri
urti
possibl
increas
intranas
pressur
nose
blow
moreov
preexist
chronic
rhinosinus
may
present
exacerb
trigger
urti
especi
combin
cigarett
smoke
postvir
olfactori
disord
includ
parosmia
phantosmia
hyposmia
anosmia
associ
common
cold
percentag
vari
differ
studi
disord
commonli
affect
middl
old
age
peopl
mainli
women
one
third
case
spontan
recoveri
may
occur
within
year
yet
specif
therapi
appli
common
cold
complic
restrict
upper
airway
common
cold
virus
includ
rv
potenti
infect
lower
airway
addit
laryngotracheobronch
bronchiol
usual
start
urti
rv
isol
children
hospit
commun
acquir
pneumonia
cap
aforement
case
bacteri
coinfect
present
rang
viral
pathogen
recogn
caus
cap
adult
lower
rate
howev
elderli
rv
infect
associ
signific
morbid
mortal
rv
critic
implic
asthma
exacerb
innat
immun
respons
defici
asthmat
individu
rv
infect
also
import
role
exacerb
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
immunocompromis
individu
includ
children
primari
immunodefici
patient
organ
transplant
malign
hivinfect
diabet
autoimmun
diseas
extrem
suscept
infect
includ
caus
common
cold
virus
identif
caus
pathogen
crucial
step
subsequ
potenti
specif
manag
sampl
identif
upper
respiratori
pathogen
includ
nasopharyng
np
aspir
np
wash
np
swab
np
swab
plu
oropharyng
op
swab
liquid
specimen
sputum
tracheal
aspir
bronchoalveolar
lavag
bal
sensit
specif
viru
detect
sampl
method
vari
significantli
antigen
detect
test
differ
cell
cultur
format
use
new
chip
detect
antibodi
respons
differ
rv
subtyp
current
develop
context
eu
project
wwwpredictaeu
news
april
pcr
prove
valuabl
diagnosi
viral
infect
particularli
rv
infect
method
suboptim
use
singl
viru
detect
quantif
assay
well
multiplex
format
allow
simultan
detect
virus
andor
subtyp
date
sever
realtim
pcr
assay
hydrolysi
probe
molecular
beacon
dual
hybrid
probe
incorpor
diagnost
devic
identifi
respiratori
pathogen
sensit
specif
high
detect
rate
costeffect
especi
multiplex
subtyp
capabl
adapt
emerg
new
virus
made
realtim
rtpcr
method
choic
amongst
respiratori
viru
detect
techniqu
furthermor
avail
multiplex
rtpcrbase
approach
significantli
improv
diagnost
yield
coinfect
molecular
base
method
also
avail
research
domain
despit
fact
molecular
test
improv
specif
diagnosi
respiratori
virus
limit
ignor
exampl
appli
viru
genom
sequenc
pcr
measur
viabl
viru
detect
low
level
viru
late
cours
infect
dual
infect
asymptomat
peopl
make
difficult
determin
clinic
relev
viru
presenc
lack
avail
extern
refer
standard
difficulti
viru
quantif
differ
level
sensit
variou
type
clinic
specimen
use
make
normal
hard
achiev
clinic
undetermin
urt
virus
spread
primarili
direct
contact
airborn
particl
aerosol
physic
intervent
includ
basic
hygien
measur
nevertheless
quit
effect
prevent
transmiss
diseas
thorough
hand
wash
effect
ethanol
sanit
gener
protect
autoinocul
minim
fingertonos
spread
help
reduc
rate
transmiss
implement
barrier
transmiss
isol
hygien
measur
wear
mask
glove
gown
effect
contain
respiratori
viru
epidem
hospit
ward
current
avail
influenza
effici
prevent
infect
recent
new
modifi
vaccinia
viru
ankara
mva
vector
encod
nucleoprotein
matrix
protein
mvanp
evalu
phase
clinic
trial
healthi
adult
found
safe
immunogen
lead
high
frequenc
respond
cell
despit
ongo
effort
licens
vaccin
parainfluenza
evalu
clinic
trial
adenovir
vaccin
deliv
oral
use
decad
prevent
respiratori
ill
usa
militari
train
instal
sever
approach
use
develop
vaccin
rsv
current
vaccin
approv
use
human
sever
virus
use
vector
rsv
vaccin
stimul
immunogen
intranas
administr
gain
attent
recent
immunostimulatori
effect
tlr
ligand
investig
encourag
result
rv
common
culprit
vaccin
develop
great
interest
obstacl
overcom
differ
serotyp
highmut
rate
viral
replic
addit
natur
humor
immun
respons
human
well
investig
vagu
data
domin
virul
strain
recent
progress
sequenc
known
rv
genom
includ
newli
character
rvc
well
analysi
rv
genom
signatur
make
percept
rv
vaccin
imposs
use
seem
past
descript
mous
model
rv
infect
immun
allow
studi
rv
antibodi
respons
insight
way
rv
misdirect
immun
respons
nonneutr
epitop
identif
recombin
protein
rv
capsid
induc
crossneutr
antibodi
divers
strain
stimul
renew
interest
rv
vaccin
avail
rsv
prophylaxi
children
high
risk
respiratori
complic
palivizumab
reduc
rsv
hospit
prematur
infant
children
age
month
hemodynam
congenit
heart
diseas
recent
motavizumab
shown
effect
result
hypersensit
advers
event
henc
yet
approv
fda
longact
antirsv
mab
administr
twice
rsv
season
develop
recent
rsv
fspecif
nanobodi
bind
epitop
high
affin
specif
found
protect
balbc
mice
rsv
infect
therapeut
intranas
administr
result
reduc
viral
replic
reduc
pulmonari
inflamm
regard
influenza
two
human
antibodi
hemagglutinin
main
target
influenzaneutr
antibodi
respons
found
protect
sever
subtyp
suggest
new
therapeut
option
sinc
sir
william
osler
said
way
treat
common
cold
contempt
littl
chang
treatment
remain
primarili
support
includ
overthecount
product
aim
symptom
relief
nsaid
acetaminophen
equal
effect
common
coldinduc
pain
malais
firstgener
antihistamin
improv
runni
nose
sneez
use
children
avoid
combin
decongest
effect
advers
effect
drowsi
dri
mouth
insomnia
dizzi
secondgener
antihistamin
seem
effect
nasal
oral
decongest
provid
short
term
relief
use
limit
advers
effect
rhiniti
medicamentosa
rebound
congest
potenti
immunomodulatori
activ
pseudoephedrin
includ
tumor
necrosi
factor
inhibit
invitro
may
explor
topic
ipratropium
reduc
rhinorrhea
sneez
effect
nasal
congest
use
well
toler
steam
inhal
unlik
common
belief
improv
symptom
associ
sever
scald
especi
children
cough
due
urti
usual
transient
selflimit
pauciti
data
exist
efficaci
cough
product
antituss
recommend
young
children
current
evid
support
use
intranas
corticosteroid
common
cold
viral
etiolog
antibiot
work
common
cold
mani
peopl
affect
antibiot
side
effect
may
also
contribut
commun
bacteri
resist
antibiot
anoth
approach
becom
popular
use
herbal
nutrit
remedi
gener
health
mainten
enhanc
immun
system
treat
common
cold
major
issu
regard
trial
herbal
remedi
standard
extract
use
combin
variou
ingredi
sever
proport
muddl
outcom
addit
occasion
strong
belief
particip
treatment
may
influenc
outcom
zinc
inhibit
rv
replic
vitro
block
rv
bind
alter
configur
viral
capsid
protein
decreas
histamin
releas
clinic
trial
reduc
averag
durat
sever
common
cold
healthi
peopl
taken
within
hour
onset
signific
reduct
durat
cold
dose
mgday
like
benefit
balanc
side
effect
bad
tast
nausea
regard
prophylact
zinc
supplement
current
firm
recommend
made
insuffici
data
vitamin
import
innat
immun
respons
urti
three
metaanalysi
publish
reach
conflict
conclus
low
oh
level
associ
increas
risk
viral
rti
children
adolesc
dosedepend
manner
monthli
administr
iu
vitamin
reduc
incid
sever
urti
healthi
adult
baselin
level
vitamin
age
dose
vitamin
need
taken
consider
vitamin
c
dose
g
daili
demonstr
therapeut
benefit
symptom
durat
sever
combin
mg
vitamin
c
mg
zinc
may
allevi
rhinorrhea
daili
supplement
larg
dose
vitamin
c
seem
prevent
common
cold
howev
modest
consist
effect
reduc
durat
sever
common
cold
demonstr
herbal
treatment
result
echinacea
inconclus
recent
random
doubleblind
placebocontrol
trial
daili
supplement
echinacea
purpurea
period
result
reduct
total
number
cold
echinacea
inhibit
viral
confirm
cold
especi
prevent
envelop
viru
infect
probiot
margin
effect
prevent
durat
cold
elderli
probiot
appear
reduc
common
cold
incid
dosedepend
way
heterogenec
studi
strain
dose
probiot
test
allow
make
safe
conclus
quercetin
inhibit
viral
endocytosi
rv
polioviru
proteas
activ
rna
polymeras
activ
rna
virus
cell
cultur
mice
treatment
quercetin
rv
infect
result
reduc
viral
load
inflammatori
respons
howev
random
blind
trial
quercetin
supplement
week
influenc
urti
rate
sever
reduct
urti
total
sick
day
sever
note
middl
age
older
subject
ingest
mg
quercetinday
arabinogalactan
long
polysaccharid
natur
found
mycobacteria
cell
wall
plant
recent
placebocontrol
trial
supplement
g
arabinogalactan
period
week
reduc
number
common
cold
episod
effect
durat
sever
episod
iotacaraageenan
antivir
effect
sever
respiratori
virus
applic
nasal
spray
contain
iotacarraageenan
three
time
per
day
allevi
local
symptom
common
cold
reduc
viral
load
nasal
mucosa
reduc
proinflammatori
mediat
howev
system
symptom
remain
cohort
children
nasal
applic
iotacaraageenan
allevi
symptom
reduc
durat
diseas
viral
load
result
lower
incid
secondari
infect
respiratori
virus
betaglucan
natur
polysaccharid
cell
wall
saccharomyc
cerevisia
fungi
bacteria
seem
immunostimulatori
effect
two
recent
trial
abl
reduc
occurr
symptomat
common
cold
infect
reduc
sever
overal
conclus
although
mani
overthecount
treatment
seem
activ
common
cold
enough
produc
robust
result
therefor
costeffect
question
effect
treatment
need
ration
approach
tackl
common
cold
develop
antivir
agent
howev
divers
etiolog
make
develop
uniform
antivir
drug
unlik
intens
investig
mani
year
howev
small
number
reach
clinic
trial
phase
even
less
bedsid
current
commerci
avail
agent
influenza
rsv
amantadin
rimantadin
first
antivir
influenza
replac
neuraminidas
inhibitor
ni
zanamivir
oseltamivir
widespread
resist
ni
use
prophylaxi
within
h
exposur
influenza
treatment
within
h
first
symptom
treatment
benefit
small
shorten
symptom
day
may
reduc
diseas
sever
laninamivir
octano
vitro
neuraminidaseinhibitori
activ
variou
influenza
b
virus
includ
subtyp
oseltamivir
resist
virus
current
develop
ribavirin
approv
therapi
lower
respiratori
tract
diseas
caus
rsv
ribavirin
inhibit
rsvspecif
ige
product
nasal
secret
improv
pulmonari
function
may
reduc
durat
sever
rsv
complic
mechan
ventil
hospit
inhibitor
rsv
entri
host
cell
target
envelop
f
protein
develop
extens
research
effort
led
discoveri
mani
potent
antivir
agent
rv
found
way
clinic
mostli
due
safeti
concern
capsidbind
inhibitor
among
first
develop
agent
pleconaril
abl
reduc
viral
load
durat
common
cold
day
concern
regard
safeti
preclud
develop
oral
treatment
outcom
phase
ii
studi
intranas
formul
pleconaril
indic
differ
incid
rv
infect
asthma
exacerb
pleconaril
placebo
group
howev
relev
public
still
pend
http
wwwclinicaltrialsgov
vapendavir
exhibit
antivir
activ
known
rva
rvb
serotyp
well
select
rv
activ
rvc
yet
establish
healthi
volunt
vapendavir
well
toler
reduc
peak
viral
load
experiment
challeng
current
evalu
treatment
rv
infect
patient
asthma
http
wwwclinicaltrialsgov
anoth
promis
molecul
rv
proteas
inhibitor
ruprintrivir
topic
administr
inhibit
symptom
experiment
rv
infect
even
administ
h
exposur
howev
natur
set
fail
amelior
clinic
manifest
viral
load
interferon
regul
immun
respons
virus
inhibit
viru
replic
enhanc
phagocytosi
cytotox
intranas
reduc
respiratori
ill
administ
either
continu
respiratori
viru
season
intermitt
postexposur
prophylaxi
famili
set
littl
effect
develop
infect
symptom
provid
infect
combin
interferon
convent
compound
provid
greater
benefit
howev
advers
reaction
nasal
irrit
mucos
friabil
bleed
limit
potenti
recent
lowdos
recombin
human
nasal
spray
develop
order
reduc
advers
reaction
seem
effici
prevent
infect
caus
influenza
b
piv
adenoviru
speci
rsv
new
insight
role
ifnb
combat
viral
infect
nomin
promis
antivir
agent
especi
asthmat
individu
context
explor
possibl
antivir
andor
antiinflammatori
mean
therapi
common
cold
varieti
pharmacolog
agent
benefici
differ
diseas
entiti
tabl
also
test
howev
inconclus
result
antivir
therapi
signific
result
vitro
sometim
anim
model
fail
show
benefit
human
practic
issu
need
administr
onset
symptom
common
cold
among
reason
current
imped
use
reduc
risk
resist
enhanc
effect
agent
combin
use
antivir
agent
differ
mechan
action
may
use
strategi
molecularbas
diagnosi
well
emerg
therapeut
option
target
specif
virus
host
immun
relat
mechan
promis
regard
develop
effect
treatment
strategi
common
cold
complic
particular
group
asthmat
immunocompromis
individu
young
children
elderli
remain
vulner
howev
sinc
common
cold
gener
mild
selflimit
condit
potenti
therapi
safe
effect
practic
side
effect
moreov
respiratori
virus
present
great
plastic
evad
mechan
may
result
drug
resist
complic
issu
research
viral
molecular
genet
highlight
evid
intim
relationship
among
virus
human
eg
influenc
select
pressur
contribut
mainten
major
histocompat
complex
mhc
divers
host
immun
respons
possibl
consequ
disturb
long
stand
eleg
balanc
elimin
viral
pathogen
care
consid
final
practic
logist
issu
time
cost
relat
limit
molecular
diagnosi
time
therapi
administr
macroeconom
compar
health
care
cost
taken
account
balanc
pro
con
common
cold
treatment
gener
popul
